APOE4 is associated with greater atrophy of the hippocampal formation in Alzheimer's disease

NeuroImage

Volumn 55, Issue 3, 2011, Pages 909-919

  Pievani, Michela ^a   Galluzzi, Samantha ^a   Thompson, Paul M ^b   Rasser, Paul E ^c,d,e   Bonetti, Matteo ^f   Frisoni, Giovanni B ^a  

^a IRCCS ISTITUTO CENTRO SAN GIOVANNI DI DIO FATEBENEFRATELLI   (Italy)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c SCHIZOPHRENIA RESEARCH INSTITUTE   (Australia)

^d UNIVERSITY OF NEWCASTLE   (Australia)

^e HUNTER MEDICAL RESEARCH INSTITUTE   (Australia)

^f Istituto Clinico Citta di Brescia   (Italy)

Author keywords

Alzheimer disease; Apolipoprotein E; Hippocampal surface; MRI

Indexed keywords

APOLIPOPROTEIN E4;

AGE; AGED; ALLELE; ALZHEIMER DISEASE; ARTICLE; BRAIN ATROPHY; BRAIN REGION; BRAIN SIZE; CLINICAL ARTICLE; COGNITION; CONTROLLED STUDY; EDUCATIONAL STATUS; FEMALE; HETEROZYGOSITY; HUMAN; MALE; MEMORY CONSOLIDATION; MINI MENTAL STATE EXAMINATION; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROTEIN EXPRESSION; SEX DIFFERENCE; THREE DIMENSIONAL IMAGING;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; APOLIPOPROTEIN E4; ATROPHY; ATTENTION; BRAIN MAPPING; CEREBRAL CORTEX; COGNITION; EDUCATION; EXECUTIVE FUNCTION; FEMALE; FUNCTIONAL LATERALITY; HETEROZYGOTE; HIPPOCAMPUS; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; MAGNETIC RESONANCE IMAGING; MALE; MEMORY; NEUROPSYCHOLOGICAL TESTS;

EID: 79952072253     PISSN: 10538119     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuroimage.2010.12.081     Document Type: Article

References (81)

1. Agosta F., Vossel K.A., Miller B.L., Migliaccio R., Bonasera S.J., Filippi M., Boxer A.L., Karydas A., Possin K.L., Gorno-Tempini M.L. Apolipoprotein E epsilon4 is associated with disease-specific effects on brain atrophy in Alzheimer's disease and frontotemporal dementia. Proc. Natl Acad. Sci. USA 2009, 106:2018-2022.
2. Amodio P., Wenin H., Del Piccolo F., Mapelli D., Montagnese S., Pellegrini A., Musto C., Gatta A., Umilta C. Variability of trail making test, symbol digit test and line trait test in normal people. A normative study taking into account age-dependent decline and sociobiological variables. Aging Clin. Exp. Res. 2002, 14:117-131.
3. Apostolova L.G., Steiner C.A., Akopyan G.G., Dutton R.A., Hayashi K.M., Toga A.W., Cummings J.L., Thompson P.M. Three-dimensional gray matter atrophy mapping in mild cognitive impairment and mild Alzheimer disease. Arch. Neurol. 2007, 64:1489-1495.
4. Apostolova L.G., Mosconi L., Thompson P.M., Green A.E., Hwang K.S., Ramirez A., Mistur R., Tsui W.H., de Leon M.J. Subregional hippocampal atrophy predicts Alzheimer's dementia in the cognitively normal. Neurobiol. Aging 2010, 31:1077-1088.
5. Arendt T., Bigl V., Tennstedt A., Arendt A. Neuronal loss in different parts of the nucleus basalis is related to neuritic plaque formation in cortical target areas in Alzheimer's disease. Neuroscience 1985, 14:1-14.
6. Barigazzi R. Esplorazione testistica della memoria di prosa. Ric. Psicol. 1987, 1:50-80.
7. Basso M., Gelernter J., Yang J., MacAvoy M.G., Varma P., Bronen R.A., van Dyck C.H. Apolipoprotein E epsilon4 is associated with atrophy of the amygdala in Alzheimer's disease. Neurobiol. Aging 2006, 27:1416-1424.
8. Bennett D.A., Wilson R.S., Schneider J.A., Evans D.A., Mendes de Leon C.F., Arnold S.E., Barnes L.L., Bienias J.L. Education modifies the relation of AD pathology to level of cognitive function in older persons. Neurology 2003, 60:1909-1915.
9. Blacker D., Haines J.L., Rodes L., Terwedow H., Go R.C., Harrell L.E., Perry R.T., Bassett S.S., Chase G., Meyers D., et al. ApoE-4 and age at onset of Alzheimer's disease: the NIMH genetics initiative. Neurology 1997, 48:139-147.
10. Bobinski M., de Leon M.J., Wegiel J., Desanti S., Convit A., Saint Louis L.A., Rusinek H., Wisniewski H.M. The histological validation of post mortem magnetic resonance imaging-determined hippocampal volume in Alzheimer's disease. Neuroscience 2000, 95:721-725.
11. Boccardi M., Sabattoli F., Testa C., Beltramello A., Soininen H., Frisoni G.B. APOE and modulation of Alzheimer's and frontotemporal dementia. Neurosci. Lett. 2004, 356:167-170.
12. Braak H., Braak E. Staging of Alzheimer's disease-related neurofibrillary changes. Neurobiol. Aging 1995, 16:271-278.
13. Brecht W.J., Harris F.M., Chang S., Tesseur I., Yu G.Q., Xu Q., Dee Fish J., Wyss-Coray T., Buttini M., Mucke L., et al. Neuron-specific apolipoprotein e4 proteolysis is associated with increased tau phosphorylation in brains of transgenic mice. J. Neurosci. 2004, 24:2527-2534.
14. Buttini M., Yu G.Q., Shockley K., Huang Y., Jones B., Masliah E., Mallory M., Yeo T., Longo F.M., Mucke L. Modulation of Alzheimer-like synaptic and cholinergic deficits in transgenic mice by human apolipoprotein E depends on isoform, aging, and overexpression of amyloid beta peptides but not on plaque formation. J. Neurosci. 2002, 22:10539-10548.
15. Caffarra P., Vezzadini G., Dieci F., Zonato F., Venneri A. Rey-osterrieth complex figure: normative values in an Italian population sample. Neurol. Sci. 2002, 22:443-447.
16. Carlesimo G.A., Caltagirone C., Gainotti G. The mental deterioration battery: normative data, diagnostic reliability and qualitative analyses of cognitive impairment. The group for the standardization of the mental deterioration battery. Eur. Neurol. 1996, 36:378-384.
17. Corder E.H., Saunders A.M., Strittmatter W.J., Schmechel D.E., Gaskell P.C., Small G.W., Roses A.D., Haines J.L., Pericak-Vance M.A. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 1993, 261:921-923.
18. Cosentino S., Scarmeas N., Helzner E., Glymour M.M., Brandt J., Albert M., Blacker D., Stern Y. APOE epsilon 4 allele predicts faster cognitive decline in mild Alzheimer disease. Neurology 2008, 70:1842-1849.
19. Cummings J.L., Mega M., Gray K., Rosenberg-Thompson S., Carusi D.A., Gornbein J. The neuropsychiatric inventory: comprehensive assessment of psychopathology in dementia. Neurology 1994, 44:2308-2314.
20. De Renzi E., Vignolo L.A. The token test: a sensitive test to detect receptive disturbances in aphasics. Brain 1962, 85:665-678.
21. Deane R., Sagare A., Hamm K., Parisi M., Lane S., Finn M.B., Holtzman D.M., Zlokovic B.V. ApoE isoform-specific disruption of amyloid beta peptide clearance from mouse brain. J. Clin. Investig. 2008, 118:4002-4013.
22. Donix M., Burggren A.C., Suthana N.A., Siddarth P., Ekstrom A.D., Krupa A.K., Jones M., Martin-Harris L., Ercoli L.M., Miller K.J., et al. Family history of Alzheimer's disease and hippocampal structure in healthy people. Am. J. Psychiatry 2010, 167:1399-1406.
23. Dubois B., Feldman H.H., Jacova C., Dekosky S.T., Barberger-Gateau P., Cummings J., Delacourte A., Galasko D., Gauthier S., Jicha G., et al. Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria. Lancet Neurol. 2007, 6:734-746.
24. Duvernoy H.M. The Human Hippocampus. Functional Anatomy, Vascularization and Serial Sections with MRI, 2nd Ed 1998, Springer Verlag, Berlin.
25. Folstein M.F., Folstein S.E., McHugh P.R. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J. Psychiatr. Res. 1975, 12:189-198.
26. Frisoni G.B., Sabattoli F., Lee A.D., Dutton R.A., Toga A.W., Thompson P.M. In vivo neuropathology of the hippocampal formation in AD: a radial mapping MR-based study. Neuroimage 2006, 32:104-110.
27. Frisoni G.B., Pievani M., Testa C., Sabattoli F., Bresciani L., Bonetti M., Beltramello A., Hayashi K.M., Toga A.W., Thompson P.M. The topography of grey matter involvement in early and late onset Alzheimer's disease. Brain 2007, 130:720-730.
28. Frisoni G.B., Ganzola R., Canu E., Rub U., Pizzini F.B., Alessandrini F., Zoccatelli G., Beltramello A., Caltagirone C., Thompson P.M. Mapping local hippocampal changes in alzheimer's disease and normal ageing with MRI at 3 Tesla. Brain 2008, 131:3266-3276.
29. Frisoni G.B., Prestia A., Rasser P.E., Bonetti M., Thompson P.M. In vivo mapping of incremental cortical atrophy from incipient to overt Alzheimer's disease. J. Neurol. 2009, 256:916-924.
30. Frisoni G.B., Fox N.C., Jack C.R., Scheltens P., Thompson P.M. The clinical use of structural MRI in Alzheimer disease. Nat. Rev. Neurol. 2010, 6:67-77.
31. Galluzzi S., Testa C., Boccardi M., Bresciani L., Benussi L., Ghidoni R., Beltramello A., Bonetti M., Bono G., Falini A., et al. The Italian brain normative archive of structural MR scans: norms for medial temporal atrophy and white matter lesions. Aging Clin. Exp. Res. 2009, 21:266-276.
32. Geroldi C., Pihlajamaki M., Laakso M.P., DeCarli C., Beltramello A., Bianchetti A., Soininen H., Trabucchi M., Frisoni G.B. APOE-epsilon4 is associated with less frontal and more medial temporal lobe atrophy in AD. Neurology 1999, 53:1825-1832.
33. Harris F.M., Brecht W.J., Xu Q., Tesseur I., Kekonius L., Wyss-Coray T., Fish J.D., Masliah E., Hopkins P.C., Scearce-Levie K., et al. Carboxyl-terminal-truncated apolipoprotein E4 causes Alzheimer's disease-like neurodegeneration and behavioral deficits in transgenic mice. Proc. Natl Acad. Sci. USA 2003, 100:10966-10971.
34. Hashimoto M., Yasuda M., Tanimukai S., Matsui M., Hirono N., Kazui H., Mori E. Apolipoprotein E epsilon 4 and the pattern of regional brain atrophy in Alzheimer's disease. Neurology 2001, 57:1461-1466.
35. Haxby J.V., Duara R., Grady C.L., Cutler N.R., Rapoport S.I. Relations between neuropsychological and cerebral metabolic asymmetries in early Alzheimer's disease. J. Cereb. Blood Flow Metab. 1985, 5:193-200.
36. He X., Cooley K., Chung C.H., Dashti N., Tang J. Apolipoprotein receptor 2 and X11 alpha/beta mediate apolipoprotein E-induced endocytosis of amyloid-beta precursor protein and beta-secretase, leading to amyloid-beta production. J. Neurosci. 2007, 27:4052-4060.
37. Hixson J.E., Vernier D.T. Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with HhaI. J. Lipid Res. 1990, 31:545-548.
38. Holmes C.J., Hoge R., Collins L., Woods R., Toga A.W., Evans A.C. Enhancement of MR images using registration for signal averaging. J. Comput. Assist. Tomogr. 1998, 22:324-333.
39. Holtzman D.M., Bales K.R., Tenkova T., Fagan A.M., Parsadanian M., Sartorius L.J., Mackey B., Olney J., McKeel D., Wozniak D., et al. Apolipoprotein E isoform-dependent amyloid deposition and neuritic degeneration in a mouse model of Alzheimer's disease. Proc. Natl Acad. Sci. USA 2000, 97:2892-2897.
40. Honea R.A., Swerdlow R.H., Vidoni E.D., Goodwin J., Burns J.M. Reduced gray matter volume in normal adults with a maternal family history of Alzheimer disease. Neurology 2010, 74:113-120.
41. Hyman B.T., Van Hoesen G.W., Damasio A.R., Barnes C.L. Alzheimer's disease: cell-specific pathology isolates the hippocampal formation. Science 1984, 225:1168-1170.
42. Jack C.R., Petersen R.C., Xu Y.C., O'Brien P.C., Waring S.C., Tangalos E.G., Smith G.E., Ivnik R.J., Thibodeau S.N., Kokmen E. Hippocampal atrophy and apolipoprotein E genotype are independently associated with Alzheimer's disease. Ann. Neurol. 1998, 43:303-310.
43. Jack C.R., Shiung M.M., Gunter J.L., O'Brien P.C., Weigand S.D., Knopman D.S., Boeve B.F., Ivnik R.J., Smith G.E., Cha R.H., et al. Comparison of different MRI brain atrophy rate measures with clinical disease progression in AD. Neurology 2004, 62:591-600.
44. Juottonen K., Lehtovirta M., Helisalmi S., Riekkinen PJ S., Soininen H. Major decrease in the volume of the entorhinal cortex in patients with Alzheimer's disease carrying the apolipoprotein E epsilon4 allele. J. Neurol. Neurosurg. Psychiatry 1998, 65:322-327.
45. Kaye J.A., Moore M.M., Dame A., Quinn J., Camicioli R., Howieson D., Corbridge E., Care B., Nesbit G., Sexton G. Asynchronous regional brain volume losses in presymptomatic to moderate AD. J. Alzheimers Dis. 2005, 8:51-56.
46. Laakso M.P., Partanen K., Riekkinen P., Lehtovirta M., Helkala E.L., Hallikainen M., Hanninen T., Vainio P., Soininen H. Hippocampal volumes in Alzheimer's disease, Parkinson's disease with and without dementia, and in vascular dementia: an MRI study. Neurology 1996, 46:678-681.
47. Laakso M.P., Lehtovirta M., Partanen K., Riekkinen P.J., Soininen H. Hippocampus in Alzheimer's disease: a 3-year follow-up MRI study. Biol. Psychiatry 2000, 47:557-561.
48. Lehtovirta M., Laakso M.P., Soininen H., Helisalmi S., Mannermaa A., Helkala E.L., Partanen K., Ryynanen M., Vainio P., Hartikainen P. Volumes of hippocampus, amygdala and frontal lobe in Alzheimer patients with different apolipoprotein E genotypes. Neuroscience 1995, 67:65-72.
49. MacDonald D., Avis D., Evans A. Multiple surface identification and matching in magnetic resonance imaging. Proc. SPIE 1994, 2359:160-169.
50. Mahley R.W. Apolipoprotein E: cholesterol transport protein with expanding role in cell biology. Science 1988, 240:622-630.
51. McKhann G., Drachman D., Folstein M., Katzman R., Price D., Stadlan E.M. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA work group under the auspices of department of health and human services task force on Alzheimer's disease. Neurology 1984, 34:939-944.
52. Meyer M.R., Tschanz J.T., Norton M.C., Welsh-Bohmer K.A., Steffens D.C., Wyse B.W., Breitner J.C. APOE genotype predicts when-not whether-one is predisposed to develop Alzheimer disease. Nat. Genet. 1998, 19:321-322.
53. Moossy J., Zubenko G.S., Martinez A.J., Rao G.R., Kopp U., Hanin I. Lateralization of brain morphologic and cholinergic abnormalities in Alzheimer's disease. Arch. Neurol. 1989, 46:639-642.
54. Morra J.H., Tu Z., Apostolova L.G., Green A.E., Avedissian C., Madsen S.K., Parikshak N., Hua X., Toga A.W., Jack C.R., et al. Automated 3D mapping of hippocampal atrophy and its clinical correlates in 400 subjects with Alzheimer's disease, mild cognitive impairment, and elderly controls. Hum. Brain Mapp. 2009, 30:2766-2788.
55. Mueller S.G., Weiner M.W. Selective effect of age, Apo e4, and Alzheimer's disease on hippocampal subfields. Hippocampus 2009, 19:558-564.
56. Novelli G., Papagno C., Capitani E., Laiacona M. Tre test clinici di ricerca e produzione lessicale. taratura su sogetti normali. Arch. Di Psicol. Neurol. Psichiatr. 1986, 47:477-506.
57. Petersen R.C., Jack C.R., Xu Y.C., Waring S.C., O'Brien P.C., Smith G.E., Ivnik R.J., Tangalos E.G., Boeve B.F., Kokmen E. Memory and MRI-based hippocampal volumes in aging and AD. Neurology 2000, 54:581-587.
58. Pievani M., Rasser P.E., Galluzzi S., Benussi L., Ghidoni R., Sabattoli F., Bonetti M., Binetti G., Thompson P.M., Frisoni G.B. Mapping the effect of APOE epsilon4 on gray matter loss in Alzheimer's disease in vivo. Neuroimage 2009, 45:1090-1098.
59. Poirier J., Davignon J., Bouthillier D., Kogan S., Bertrand P., Gauthier S. Apolipoprotein E polymorphism and Alzheimer's disease. Lancet 1993, 342:697-699.
60. Rasser P.E., Johnston P., Lagopoulos J., Ward P., Schall U., Thienel R., Bender S., Toga A., Thompson P.M. Functional MRI BOLD response to Tower of London performance of first-episode schizophrenia patients using cortical pattern matching. Neuroimage 2005, 26:941-951.
61. Reitan R. Validity of the trail making test as an indicator of organic brain damage. Percept. Mot. Skills 1958, 8:271-276.
62. Scahill R.I., Schott J.M., Stevens J.M., Rossor M.N., Fox N.C. Mapping the evolution of regional atrophy in Alzheimer's disease: unbiased analysis of fluid-registered serial MRI. Proc. Natl Acad. Sci. USA 2002, 99:4703-4707.
63. Schmechel D.E., Saunders A.M., Strittmatter W.J., Crain B.J., Hulette C.M., Joo S.H., Pericak-Vance M.A., Goldgaber D., Roses A.D. Increased amyloid beta-peptide deposition in cerebral cortex as a consequence of apolipoprotein E genotype in late-onset Alzheimer disease. Proc. Natl Acad. Sci. USA 1993, 90:9649-9653.
64. Schonheit B., Zarski R., Ohm T.G. Spatial and temporal relationships between plaques and tangles in Alzheimer-pathology. Neurobiol. Aging 2004, 25:697-711.
65. Shattuck D.W., Sandor-Leahy S.R., Schaper K.A., Rottenberg D.A., Leahy R.M. Magnetic resonance image tissue classification using a partial volume model. Neuroimage 2001, 13:856-876.
66. Shi F., Liu B., Zhou Y., Yu C., Jiang T. Hippocampal volume and asymmetry in mild cognitive impairment and Alzheimer's disease: meta-analyses of MRI studies. Hippocampus 2009, 19:1055-1064.
67. Simic G., Kostovic I., Winblad B., Bogdanovic N. Volume and number of neurons of the human hippocampal formation in normal aging and Alzheimer's disease. J. Comp. Neurol. 1997, 379:482-494.
68. Snowden J.S., Stopford C.L., Julien C.L., Thompson J.C., Davidson Y., Gibbons L., Pritchard A., Lendon C.L., Richardson A.M., Varma A., et al. Cognitive phenotypes in Alzheimer's disease and genetic risk. Cortex 2007, 43:835-845.
69. Spinnler H., Tognoni G. Taratura e standardizzazione italiana di test neuropsicologici. Ital. J. Neurol. Sci. 1987, 7:1-120.
70. Squire L.R., Stark C.E., Clark R.E. The medial temporal lobe. Annu. Rev. Neurosci. 2004, 27:279-306.
71. Strittmatter W.J., Saunders A.M., Schmechel D., Pericak-Vance M., Enghild J., Salvesen G.S., Roses A.D. Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proc. Natl Acad. Sci. USA 1993, 90:1977-1981.
72. Tesseur I., Van Dorpe J., Spittaels K., Van den Haute C., Moechars D., Van Leuven F. Expression of human apolipoprotein E4 in neurons causes hyperphosphorylation of protein tau in the brains of transgenic mice. Am. J. Pathol. 2000, 156:951-964.
73. Teter B., Xu P.T., Gilbert J.R., Roses A.D., Galasko D., Cole G.M. Defective neuronal sprouting by human apolipoprotein E4 is a gain-of-negative function. J. Neurosci. Res. 2002, 68:331-336.
74. Thompson P.M., Hayashi K.M., de Zubicaray G., Janke A.L., Rose S.E., Semple J., Herman D., Hong M.S., Dittmer S.S., Doddrell D.M., et al. Dynamics of gray matter loss in Alzheimer's disease. J. Neurosci. 2003, 23:994-1005.
75. Thompson P.M., Hayashi K.M., De Zubicaray G.I., Janke A.L., Rose S.E., Semple J., Hong M.S., Herman D.H., Gravano D., Doddrell D.M., et al. Mapping hippocampal and ventricular change in Alzheimer disease. Neuroimage 2004, 22:1754-1766.
76. Van Essen D.C. Windows on the brain. The emerging role of atlases and databases in neuroscience. Curr. Op. Neurobiol. 2002, 12:574-579.
77. Wahlund L.O., Barkhof F., Fazekas F., Bronge L., Augustin M., Sjogren M., Wallin A., Ader H., Leys D., Pantoni L., et al. A new rating scale for age-related white matter changes applicable to MRI and CT. Stroke 2001, 32:1318-1322.
78. Wang L., Miller J.P., Gado M.H., McKeel D.W., Rothermich M., Miller M.I., Morris J.C., Csernansky J.G. Abnormalities of hippocampal surface structure in very mild dementia of the Alzheimer type. Neuroimage 2006, 30:52-60.
79. Wilcock G.K., Esiri M.M. Asymmetry of pathology in Alzheimer's disease. J. Neurol. Neurosurg. Psychiatry 1987, 50:1384-1386.
80. Wolk D.A., Dickerson B.C., Alzheimer's Disease Neuroimaging Initiative Apolipoprotein E (APOE) genotype has dissociable effects on memory and attentional-executive network function in Alzheimer's disease. PNAS 2010, 107:10256-10261.
81. Ye S., Huang Y., Mullendorff K., Dong L., Giedt G., Meng E.C., Cohen F.E., Kuntz I.D., Weisgraber K.H., Mahley R.W. Apolipoprotein (apo) E4 enhances amyloid beta peptide production in cultured neuronal cells: ApoE structure as a potential therapeutic target. Proc. Natl Acad. Sci. USA 2005, 102:18700-18705.